Foundation Medicine, which offers diagnostic cancer analyses that provide patient specific data for physicians, raised $106 million by offering 5.9 million shares (up from an expected 5.0 million) at $18, above the range of $14 to $16. Foundation Medicine plans to list on the NASDAQ under the symbol FMI. Foundation Medicine initially filed confidentially on 6/24/2013. Goldman Sachs and J.P. Morgan acted as lead managers on the deal.
